Cytek Biosciences (CTKB) EBITDA (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of EBITDA data on file, last reported at -$18.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 55.81% year-over-year to -$18.7 million; the trailing twelve-month figure through Mar 2026 stood at -$71.0 million (down 589.04% YoY), and the FY2025 full-year result was -$64.3 million, down 1259.7% from the prior year.
• EBITDA for Q1 2026 stood at -$18.7 million, up from -$42.7 million in the prior quarter.
• Across five years, EBITDA topped out at $9.6 million in Q4 2024 and bottomed at -$42.7 million in Q4 2025.
• The 5-year median for EBITDA is -$5.0 million (2025), against an average of -$5.8 million.
• The widest annual swing landed in 2022, when EBITDA surged 169.63%; it then sank 823.04% in 2023.
• A 5-year view of EBITDA shows it stood at $3.6 million in 2022, then surged by 63.53% to $5.8 million in 2023, then surged by 64.58% to $9.6 million in 2024, then plunged by 546.32% to -$42.7 million in 2025, then surged by 56.07% to -$18.7 million in 2026.
• The last three EBITDA figures came in at -$18.7 million (Q1 2026), -$42.7 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.

Peer Comparison